Education
About Us
Working with TipRanks
Follow Us
Anebulo Pharmaceuticals, Inc. (ANEB)
:ANEB
Total Valuation
Anebulo Pharmaceuticals has a market cap or net worth of $44.37M. The enterprise value is $48.65M.
Market Cap$44.37M
Enterprise Value$48.65M
Share Statistics
Anebulo Pharmaceuticals has 41,084,732 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,084,732
Owned by Insiders78.18%
Owned by Institutions0.85%
Financial Efficiency
Anebulo Pharmaceuticals’s return on equity (ROE) is -2.15 and return on invested capital (ROIC) is -217.93%.
Return on Equity (ROE)-2.15
Return on Assets (ROA)-2.01
Return on Invested Capital (ROIC)-217.93%
Return on Capital Employed (ROCE)-2.18
Revenue Per Employee0.00
Profits Per Employee-4.10M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Anebulo Pharmaceuticals is -8.44. Anebulo Pharmaceuticals’s PEG ratio is 0.26.
PE Ratio-8.44
PS Ratio―
PB Ratio18.15
Price to Fair Value18.15
Price to FCF-8.55
Price to Operating Cash Flow-8.55
PEG Ratio0.26
Income Statement
In the last 12 months, Anebulo Pharmaceuticals had revenue of 0.00 and earned -8.20M in profits. Earnings per share was -0.32.
Revenue0.00
Gross Profit0.00
Operating Income-8.31M
Pretax Income-8.20M
Net Income-8.20M
EBITDA-8.05M
Earnings Per Share (EPS)-0.32
Cash Flow
In the last 12 months, operating cash flow was -6.65M and capital expenditures 0.00, giving a free cash flow of -6.65M billion.
Operating Cash Flow-6.65M
Free Cash Flow-6.65M
Free Cash Flow per Share-0.16
Dividends & Yields
Anebulo Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.57
52-Week Price Change-60.00%
50-Day Moving Average1.26
200-Day Moving Average1.67
Relative Strength Index (RSI)46.43
Average Volume (3m)37.59K
Important Dates
Anebulo Pharmaceuticals upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateFeb 14, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Anebulo Pharmaceuticals as a current ratio of 13.46, with Debt / Equity ratio of 0.00%
Current Ratio13.46
Quick Ratio13.46
Debt to Market Cap0.00
Net Debt to EBITDA0.38
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Anebulo Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Anebulo Pharmaceuticals EV to EBITDA ratio is -8.21, with an EV/FCF ratio of -8.17.
EV to Sales0.00
EV to EBITDA-8.21
EV to Free Cash Flow-8.17
EV to Operating Cash Flow-8.17
Balance Sheet
Anebulo Pharmaceuticals has $15.00M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$15.00M billion.
Cash & Marketable Securities$15.00M
Total Debt$0.00
Net Cash-$15.00M
Net Cash Per Share-$0.37
Tangible Book Value Per Share$0.15
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Anebulo Pharmaceuticals is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside724.74% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast28.92%